IBM's Watson for Genomics technology is expected to help in the department's precision oncology programme by providing information to help physicians identify precision treatment options for almost 30 times more patients than could be previously served.
The collaboration is expected to greatly speed up the ability of VA doctors to help identify precision treatment options for veterans. Scientists and pathologists will sequence DNA for cancer patients, then feed de-identified genetic alteration files into Watson. Watson will generate a report for physicians that identifies the likely cancer-causing mutations and possible treatment options to target those specific mutations through a comprehensive review of existing medical literature - a data-intensive process that has been time-consuming and difficult to scale in the past.
Genetic alterations are responsible for most cancers, but it remains challenging for most clinicians to deliver on the promise of precision medicine due to the sheer volume of data surrounding each decision that needs to be made", stated Department of Veterans Affairs Under Secretary for Health Dr. David J. Shulkin. "By applying Watson to this problem, we see an opportunity to scale access to precision medicine for America's veterans, a group most deserving of the best care in the world."
Veterans of war experience disproportionately high rates of cancer diagnosis and mortality and as America's largest integrated health system, VA serves 3.5 percent of the nation's cancer patients - the largest group of cancer patients in the country. Watson is expected to facilitate rapid access for veterans to personalized care, particularly for patients with advanced cancer.
"The power of cognitive computing is its ability to ingest, understand and find patterns in massive volumes of disparate data - which is one of the fundamental barriers to precision medicine today", stated John Kelly, senior vice president, IBM Research and Cognitive Solutions. "In addition to helping advance clinical care, data and insights from Watson will also be shared with the research community, creating tremendous potential benefits for patients, researchers and society. Watson Health is IBM's own moonshot, and we share the Vice President's vision and goals to advance the fight against cancer through data and collaboration."
As a tool to help doctors evaluate treatment options for their patients, Watson for Genomics produces a list of potential therapies ranked by levels of evidence with links to associated research and clinical trials for physicians to consider. This information could help inform VA's health care professionals and veterans of promising new cancer treatments. The VA's top priorities of access to and quality of care could be enhanced through this innovative technology.
IBM's commitment to VA follows more than 2 years of collaboration with more than 20 leading cancer institutes to train and validate Watson for Genomics. Early results from academic medical centres that are using Watson for Genomics show that the technology provides insights that match what a team of scientists and clinicians - a molecular tumor board - would uncover when analyzing genome sequencing data and suggesting potential treatment options to target cancer mutations.
Both the VA and IBM have a history of innovation in the battle against cancer. The VA invested $52 million in 2015 to support nearly 250 cancer research projects, with a particular focus on better understanding and preventing cancers that are prevalent in the veteran population. IBM researchers have developed cognitive computing technologies that enable researchers and clinicians to draw insights from vast, disparate data sources, including structured and unstructured data. IBM is collaborating with health care organisations to apply the cognitive computing power of Watson to the data challenges of cancer.
The collaboration between IBM and the VA is also expected to help advance genomic research. Findings related to the identified treatment options in the literature will be shared with the academic community.